

Invitation to webcast for Q2 2023/2024

Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET.

Anders Rylander, CEO, Warren Cresswell, President of Biovica Americas, Henrik Winther, SVP Business Development and Anders Morén, CFO will present and answer questions. Please register for the webcast and watch it live here: [link](#).

Contact

Anders Rylander, CEO

Phone: +46 76 666 16 47

E-mail: anders.rylander@biovica.com

Anders Morén, CFO

Phone: +46 73 125 92 46

E-mail: anders.moren@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum[®] TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum[®] TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum[®] TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com

Attachments

[Invitation to webcast for Q2 2023/2024](#)